GLP-1 Clinical Trial Synthesis (2026)

The GLP-1 receptor agonist class has produced the largest weight-loss and cardiometabolic effect sizes in modern pharmacology. Here is a consolidated view of the trials shaping the field in 2026.

Semaglutide, STEP and SUSTAIN Programs

STEP-1 (NEJM, 2021): once-weekly semaglutide 2.4 mg produced −14.9% mean body weight at 68 weeks vs −2.4% placebo, in adults with obesity without diabetes.(1)

STEP-2 / STEP-3 / STEP-4: confirmed efficacy across diabetic populations, with intensive lifestyle, and demonstrated weight regain on withdrawal.

SUSTAIN-6 (NEJM, 2016): semaglutide reduced major adverse cardiovascular events (MACE) by 26% in type 2 diabetes.

SELECT (NEJM, 2023): in patients with established CV disease and obesity (no diabetes), semaglutide cut MACE by 20%, a class-defining cardiovascular outcomes result.(2)

Tirzepatide, SURMOUNT and SURPASS

Dual GIP/GLP-1 agonist.

SURMOUNT-1 (NEJM, 2022): tirzepatide 15 mg weekly produced −20.9% body weight at 72 weeks. Highest pharmacological weight reduction reported at the time.(3)

SURPASS-2 / SURPASS-3: superior A1c reduction (−2.3% absolute on max dose) vs semaglutide and insulin degludec respectively.

SURMOUNT-OSA (2024): tirzepatide reduced apnea-hypopnea index by ~30 events/hour in obese OSA patients.

Retatrutide, Triple Agonist (Phase II)

Jastreboff et al., NEJM 2023: retatrutide (GLP-1 / GIP / glucagon) produced −24.2% body weight at 48 weeks at the 12 mg dose.(4) Phase III (TRIUMPH program) is ongoing in 2026.

Cardiovascular Outcomes Class Effect

Across SUSTAIN-6, REWIND (dulaglutide), LEADER (liraglutide) and SELECT, GLP-1 agonists consistently reduce MACE in high-risk populations. The mechanism is multifactorial: weight loss, BP reduction, anti-inflammatory effects, plaque modulation.

Tolerability, What Trials Show

• •GI side effects (nausea, vomiting, diarrhea): 30–50% of subjects, dose-dependent, mostly transient
• •Gallbladder events: small but consistent signal
• •Pancreatitis: no causal link in pooled analyses
• •Lean mass loss: ~25–40% of weight lost is lean mass without resistance training

Practical Research Comparisons

Open Questions for 2026+

• •Optimal de-escalation strategy to avoid weight regain
• •Long-term lean mass preservation protocols
• •Pediatric and adolescent expansion (STEP TEENS already positive)
• •Cardiovascular benefit in non-diabetic, non-obese populations

Cross-Trial Weight and HbA1c Signals

Across the SUSTAIN and STEP program readouts, semaglutide 2.4 mg weekly produced mean placebo-adjusted weight reductions of roughly 12–15% at 68 weeks. The SURMOUNT-1 trial of tirzepatide 15 mg weekly reported mean reductions of roughly 20.9% over the same window, with HbA1c reductions of 1.5–2.1 percentage points in participants with type 2 diabetes.

Cardiovascular Endpoints

SELECT (semaglutide 2.4 mg) reported a 20% reduction in major adverse cardiovascular events in overweight and obese adults with established cardiovascular disease but without diabetes, the first weight-loss agent to hit a hard CV endpoint. Tirzepatide's CV outcomes trial (SURPASS-CVOT) is still enrolling as of 2026.

Retatrutide (Triple Agonist)

Phase 2 data on retatrutide (GIP/GLP-1/glucagon triple agonist) reported mean weight loss of 24.2% at 48 weeks on the 12 mg dose, the largest signal reported to date for a metabolic peptide. Phase 3 readouts are anticipated in late 2026 through 2027.

Adverse Event Profile

Gastrointestinal effects (nausea, diarrhea, vomiting) dominate the adverse-event columns across all GLP-1 trials, typically peaking during dose-escalation windows and attenuating over 8–12 weeks. Pancreatitis and gallbladder events are reported at low but non-zero rates.

Frequently Asked Questions

Which GLP-1 agent has produced the largest weight-loss signal?

As of mid-2026, retatrutide (triple agonist) leads Phase 2 data at ~24% mean loss; tirzepatide leads approved Phase 3 data at ~21%.

Has any GLP-1 reduced cardiovascular events in non-diabetics?

Yes. The SELECT trial reported a 20% MACE reduction with semaglutide 2.4 mg in overweight/obese adults with prior CV disease and without diabetes.

Are GLP-1 effects reversible on discontinuation?

Yes. STEP-4 and other extension trials show substantial weight regain within 12 months of discontinuation, consistent with an appetite-regulating rather than adipocyte-remodeling mechanism.

What is the most common reason for trial discontinuation?

Gastrointestinal adverse events during dose escalation.

References

1. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. PMID: 33567185.
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity. N Engl J Med. 2023 Dec 14. PMID: 37952131.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. PMID: 35658024.
4. Jastreboff AM, Kaplan LM, Frías JP, et al; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. PMID: 37366315.